Catarina Silva, MSc,  —

Adults with cystic fibrosis (CF) are less active than they should be, although they have comparable activity levels to people without the genetic disorder, according to a recent review. The review also showed that there are not enough studies that objectively assess physical activity levels in CF. Therefore,…

More than 60 cystic fibrosis experts strongly support Relizorb being made available to CF patients on tube feeding, pushing in a commentary for the insurance coverage that’s generally denied this digestive enzyme cartridge, and inviting “the CF community” to become advocates of better patient access to the device. Their opinion…

Vertex Pharmaceuticals and Arbor Biotechnologies have established a partnership to discover new proteins to advance the development of gene therapies for cystic fibrosis. The companies also plan to develop new genome-editing approaches for four other diseases but haven’t revealed which ones yet. Under the terms of the…

Prepubescent children with cystic fibrosis (CF) have lower bone density compared to healthy children, and findings are comparable using two distinct bone density scanning methods, researchers report. The study that supports that conclusion, “Peripheral quantitative computed tomography detects differences at the radius in prepubertal children with cystic…

Pseudomonas aeruginosa is a bacteria that commonly infects cystic fibrosis patients. Now, researchers have designed a synthetic peptide that blocks the ability of these bacteria to cause disease. This discovery might be crucial in fighting infectious diseases and preventing bacteria from becoming resistant to nearly all the antibiotic drug options available.

Synspira has started a Phase 1a clinical trial to determine the safety and tolerability of its cystic fibrosis therapy candidate SNSP113 in healthy volunteers and eventually in patients with stable CF. The dosing of the first participant marked the trial kick-off, the company announced. “SNSP113 is the first clinical [trial]…

Preclinical data shows that AB-PA01 can reduce biofilms produced by the bacteria Pseudomonas aeruginosa, a major cause of lung infections in cystic fibrosis patients, scientists report. The study,  “Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients,”…